CALGENT BIOTECHNOLOGY CO.
Led by Dr. Yun Yen, the team aims for a first-in-class, low toxicity oral anti-cancer drug namely MPT0L056, an ITCH E3 ubiquitin ligase inhibitor which is to be marketed for treating multiple myeloma and pancreatic cancer. MPT0L056 features include: 1. High cytotoxic activity and selectivity against cancer cells. MPT0L056 selectively inhibits the growth of cancer cells, presenting a broader therapeutic window. 2. Specific inhibition toward ITCH E3 ubiquitin ligase activity. Compared with other commercially available ubiquitin proteasome pathway (UPP) inhibitors, for example Bortezomib, MPT0L056 causes fewer side effects. 3. A good oral bioavailability. MPT0L056 is an oral anti-cancer drug.
CALGENT BIOTECHNOLOGY CO.
Industry:
Biotechnology
Founded:
2019-08-19
Address:
Taipei, T'ai-pei, Taiwan
Country:
Taiwan
Total Employee:
1+
Status:
Active
Similar Organizations
Microdermis
Microdermis manufactures and markets skin care products for skin repair and protection, antimicrobial, and dental skin care.
More informations about "CALGENT BIOTECHNOLOGY CO."
ABOUT - Calgent Biotechnology Co. Ltd. | Novel Drugs | Unmet …
CALGENT, a spin-off company of Taipei Medical University (TMU), was established in 2019 and thrives on applying science and technology to drug development. We are committed to …See details»
CALGENT BIOTECHNOLOGY CO. - Crunchbase Company Profile
Organization. CALGENT BIOTECHNOLOGY CO. Connect to CRM . Save . Summary. People. Signals & News. Similar Companies. About. Low toxicity oral anti-cancer drug -MPT0L056, an …See details»
Biotech (incl. agriculture), Biologics (incl. regenerative med.), Small ...
CALGENT primarily focuses on the process from preclinical to clinical proof of concept (PoC) during the drug development value chain. CALGENT primarily targets highly novel projects …See details»
Calgent Biotechnology Co. Ltd. - Drug pipelines, Patents ... - Patsnap
Explore Calgent Biotechnology Co. Ltd. with its drug pipeline, therapeutic area, technology platform, 1 clinical trial, and 2 literature, Disease Domain:Neoplasms, Endocrinology and …See details»
CAL056 - Calgent Biotechnology Co. Ltd. | Novel Drugs …
The low toxicity found in toxicology studies indicates its wide therapeutic window. CAL056 has been granted Orphan Drug Designation for the treatment of multiple myeloma and is currently in Phase I trial for evaluating the safety, PK, …See details»
Calgent Biotechnology - Overview, News & Similar companies
View Calgent Biotechnology (www.calgent.com) location in New South Wales, Australia , revenue, industry and description. Find related and similar companies as well as employees by title and …See details»
CALGENT BIOTECHNOLOGY CO:Company Profile & Technical …
CALGENT BIOTECHNOLOGY CO is headquartered in China Taiwan Province. CALGENT BIOTECHNOLOGY CO was founded in 2019. CALGENT BIOTECHNOLOGY CO has a total …See details»
CALGENT BIOTECHNOLOGY CO. - Crunchbase
Organization. CALGENT BIOTECHNOLOGY CO. Connect to CRM . Save . Summary. People. Signals & News. Similar Companies. Similar Companies. ... CALGENT BIOTECHNOLOGY …See details»
CALGENT BIOTECHNOLOGY CO., LTD. - 公司登記查詢中心
Original Registration Date: 20200415: Date of Last Change: 20230105: Company Name in English: CALGENT BIOTECHNOLOGY CO., LTD. Business Address in EnglishSee details»
Calgent Biotechnology - Company Profile - Tracxn
Calgent Biotechnology - Developer of therapeutics for cancer and immunological disorders. Calgent Biotechnology - Company Profile - Tracxn JavaScript is disabled in your browser. …See details»
CAL-056 - Drug Targets, Indications, Patents - Synapse
CAL-056, Initially developed by Calgent Biotechnology Co. Ltd., Now, its global highest R&D status is Preclinical, Therapeutic Areas: Immune System Diseases,Respiratory Diseases,Skin …See details»
CALGENT BIOTECHNOLOGY CO., LTD. - US Patent and Trademark …
Patent applications and USPTO patent grants for CALGENT BIOTECHNOLOGY CO., LTD..The latest application filed is for "compounds and pharmaceutical composition associated with …See details»
NEWS - Calgent Biotechnology Co. Ltd. | Novel Drugs | Unmet …
Calgent Biotechnology Co. Ltd. | Novel Drugs | Unmet Medical Needs. NEWS 【2023/5/4】Translation Research Center of Calgent Biotech was formally established READ MORE → …See details»
Calgent Biotechnology Co. Ltd. (博蔚医药生物科技股份有限公司)
了解Calgent Biotechnology Co. Ltd. (博蔚医药生物科技股份有限公司)公司的药物管线，治疗领域，技术平台，以及它的1项临床试, 2篇新闻和2篇文献，疾病领域:肿瘤，血液及淋巴系统疾 …See details»
CAL-002 - Drug Targets, Indications, Patents - Synapse
CAL-002, Initially developed by Calgent Biotechnology Co. Ltd., Now, its global highest R&D status is Preclinical, Therapeutic Areas: Neoplasms,Digestive System …See details»
CALGENT BIOTECHNOLOGY CO:Financial,Market Cap,Revenue
Discovery Company profile page for CALGENT BIOTECHNOLOGY CO including technical research,competitor monitor,market trends,company profile& stock symbolSee details»
CAL056 mesylate in Resistant or Refractory Solid Tumors - ICH GCP
Dec 15, 2020 April 23, 2023 updated by: Calgent Biotechnology Co., Ltd. A Phase I, Multi-center, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, and …See details»
Patents Assigned to Calgent Biotechnology Co., Ltd ... - Justia …
Assignee: Calgent Biotechnology Co., Ltd. Inventors: Yun Yen, Jing-ping Liou, Shiow-lin Pan Aminonaphthoquinone compounds for treatment and/or prevention of fibrosis diseases. Patent …See details»
CAL-005 - Drug Targets, Indications, Patents - Synapse
CAL-005, Initially developed by Calgent Biotechnology Co. Ltd., Now, its global highest R&D status is Preclinical, Therapeutic Areas: Neoplasms,Infectious Diseases,Digestive System …See details»